| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011994098 |
| P356 | DOI | 10.1186/BCR2113 |
| P932 | PMC publication ID | 2575527 |
| P698 | PubMed publication ID | 18611244 |
| P5875 | ResearchGate publication ID | 5240007 |
| P2093 | author name string | Bin Chen | |
| Shiuan Chen | |||
| Dean B Evans | |||
| Joanna Lisztwan | |||
| Astrid Pornon | |||
| P2860 | cites work | Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2 | Q24672372 |
| Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells | Q24810622 | ||
| Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer | Q28298007 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Role of the insulin-like growth factor family in cancer development and progression | Q34038191 | ||
| Letrozole: a review of its use in postmenopausal women with breast cancer | Q34322778 | ||
| Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. | Q34351722 | ||
| A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer | Q34563755 | ||
| Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. | Q34578377 | ||
| Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis | Q34790667 | ||
| Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells | Q35147146 | ||
| Aromatase inhibitors in breast cancer | Q35152297 | ||
| Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer | Q35445154 | ||
| Insulin-like growth factor ligands, receptors, and binding proteins in cancer. | Q36004697 | ||
| Cross talk between estrogen receptor and IGF signaling in normal mammary gland development and breast cancer | Q36027816 | ||
| Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer | Q36035275 | ||
| Therapeutic observations in MCF-7 aromatase xenografts. | Q36035298 | ||
| Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling | Q36185627 | ||
| Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. | Q36236624 | ||
| Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. | Q36236645 | ||
| Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? | Q36574547 | ||
| Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer | Q36583516 | ||
| Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line | Q36618874 | ||
| Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor | Q36696132 | ||
| Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer | Q36953160 | ||
| Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens | Q40138504 | ||
| Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells | Q40167107 | ||
| Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. | Q40355980 | ||
| Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole | Q40408917 | ||
| The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation | Q40427640 | ||
| Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. | Q40427655 | ||
| Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor | Q40427703 | ||
| Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. | Q40601488 | ||
| A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. | Q40607057 | ||
| Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens | Q40614262 | ||
| Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth | Q40789384 | ||
| IGF system components as prognostic markers in breast cancer. | Q41727250 | ||
| Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen | Q41817542 | ||
| Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion | Q42486018 | ||
| In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase | Q42799629 | ||
| Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells | Q42816936 | ||
| Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). | Q43597891 | ||
| Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group | Q43607761 | ||
| Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial | Q43739514 | ||
| Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study | Q43873472 | ||
| Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis | Q44043137 | ||
| Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer | Q44187688 | ||
| Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group | Q44459245 | ||
| A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer | Q44613177 | ||
| Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model | Q44802938 | ||
| Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. | Q46365836 | ||
| Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. | Q52523736 | ||
| Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). | Q53985281 | ||
| Circulating concentrations of insulin-like growth factor I and risk of breast cancer | Q57751183 | ||
| Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 | Q58466062 | ||
| Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expressionin Vitroandin Vivo | Q62267728 | ||
| Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen | Q68123446 | ||
| Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer | Q70046632 | ||
| Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors | Q70062828 | ||
| Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis | Q73510884 | ||
| The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components | Q74248231 | ||
| The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers | Q80081696 | ||
| Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation | Q80213822 | ||
| P433 | issue | 4 | |
| P304 | page(s) | R56 | |
| P577 | publication date | 2008-07-08 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer | |
| P478 | volume | 10 |
| Q35620283 | A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression |
| Q35972102 | Cell death signaling and anticancer therapy |
| Q91570275 | Central aromatization: A dramatic and responsive defense against threat and trauma to the vertebrate brain |
| Q37323603 | Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. |
| Q33276057 | Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR |
| Q37607183 | Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth |
| Q34352011 | Growth hormone potentiates 17β-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling |
| Q34774874 | High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy |
| Q37493335 | Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice |
| Q29619495 | Insulin and insulin-like growth factor signalling in neoplasia |
| Q34737272 | Interaction between IGF-IR and ER induced by E2 and IGF-I |
| Q33658276 | Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors |
| Q35889534 | Luminal-B breast cancer and novel therapeutic targets |
| Q37238625 | Neuroprotective actions of brain aromatase |
| Q34440701 | Potential chemopreventive agents based on the structure of the lead compound 2-bromo-1-hydroxyphenazine, isolated from Streptomyces species, strain CNS284 |
| Q37859024 | Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer |
| Q91259737 | The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer |
| Q38843932 | The involvement of survivin in insulin-like growth factor 1-induced epithelial-mesenchymal transition in gastric cancer |
| Q36180128 | The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells |
| Q38097400 | The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer |
| Q37993267 | Traumatized and inflamed--but resilient: glial aromatization and the avian brain |
| Q39753305 | Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance |
| Q35683561 | erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines |
Search more.